IRMD · Iradimed Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.98M | - | $21.20M | $20.41M | $19.51M | - | $18.33M | $17.93M | $17.60M | - |
| Cost of Revenue | $5.17M | - | $4.71M | $4.45M | $4.67M | - | $4.13M | $3.92M | $4.21M | - |
| Gross Profit | $16.81M | - | $16.49M | $15.95M | $14.84M | - | $14.19M | $14.01M | $13.39M | - |
| R&D | $956.0K | - | $674.4K | $877.4K | $624.2K | - | $639.5K | $801.1K | $3.83M | - |
| SG&A | $4.57M | - | $4.36M | $4.28M | $4.61M | - | $3.97M | $4.10M | $3.99M | - |
| Total Operating Expenses | $9.58M | - | $9.66M | $9.17M | $9.41M | - | $8.40M | $8.38M | $8.64M | - |
| D&A | $455.0K | - | $256.3K | $135.7K | $194.1K | - | $164.6K | $141.7K | $226.1K | - |
| Operating Income | $7.24M | - | $6.83M | $6.79M | $5.43M | - | $5.79M | $5.63M | $4.75M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $1.95M | - | $1.72M | $1.55M | $1.26M | - | $1.37M | $1.37M | $1.11M | - |
| Net Income | $5.82M | - | $5.58M | $5.77M | $4.69M | - | $5.05M | $4.90M | $4.14M | - |
| EPS - Basic | $0.46 | - | $0.44 | $0.45 | $0.37 | - | $0.40 | $0.39 | $0.33 | - |
| EPS - Diluted | $0.45 | - | $0.43 | $0.45 | $0.37 | - | $0.40 | $0.38 | $0.32 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $56.37M | $51.16M | $56.53M | $53.00M | $50.33M | $52.23M | $51.72M | $48.54M | $45.13M | $49.76M |
| Accounts Receivable | $13.41M | $13.67M | $13.86M | $10.92M | $12.71M | $10.56M | $10.36M | $11.95M | $13.03M | $12.22M |
| Inventory | $11.88M | $11.62M | $11.73M | $11.20M | $10.56M | $10.40M | $11.25M | $12.07M | $12.70M | $12.82M |
| Accounts Payable | $2.18M | $1.82M | $2.33M | $1.90M | $2.59M | $1.90M | $1.40M | $1.12M | $1.29M | $1.86M |
| Current Assets | $86.42M | $81.20M | $84.92M | $77.37M | $75.14M | $75.24M | $74.29M | $73.58M | $71.89M | $76.00M |
| Total Assets | $114.39M | $108.78M | $114.72M | $106.45M | $101.73M | $98.33M | $94.25M | $89.95M | $88.01M | $92.16M |
| Current Liabilities | $12.12M | $10.18M | $12.80M | $8.81M | $8.47M | $8.51M | $8.06M | $7.46M | $7.62M | $16.33M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $15.88M | $14.16M | $16.37M | $12.15M | $11.68M | $11.51M | $10.81M | $10.28M | $11.89M | $20.74M |
| Stockholders' Equity | $98.51M | $94.62M | $98.35M | $94.30M | $90.05M | $86.82M | $83.43M | $79.67M | $76.12M | $71.42M |
| Retained Earnings | $67.49M | $64.23M | $66.34M | $62.93M | $59.32M | $56.79M | $53.55M | $50.40M | $47.39M | $43.26M |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $8.29M | - | - | - | $4.29M | - | - | - | $3.88M | - |
| Investing Cash Flow | ($469.0K) | - | - | - | ($3.92M) | - | - | - | ($478.8K) | - |
| Financing Cash Flow | ($2.61M) | - | - | - | ($2.28M) | - | - | - | ($8.04M) | - |
| CapEx | $403.0K | - | - | - | $3.70M | - | - | - | $270.6K | - |
| Free Cash Flow | $7.89M | - | - | - | $594.6K | - | - | - | $3.61M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 76.5% | - | 77.8% | 78.2% | 76.1% | - | 77.4% | 78.1% | 76.1% | - |
| Operating margin | 32.9% | - | 32.2% | 33.3% | 27.8% | - | 31.6% | 31.4% | 27.0% | - |
| EBITDA margin | 35.0% | - | 33.4% | 33.9% | 28.8% | - | 32.5% | 32.2% | 28.3% | - |
| Net margin | 26.5% | - | 26.3% | 28.3% | 24.0% | - | 27.6% | 27.3% | 23.5% | - |
| Free cash flow margin | 35.9% | - | - | - | 3.0% | - | - | - | 20.5% | - |
| FCF / Net income | 1.36 | - | - | - | 0.13 | - | - | - | 0.87 | - |
| R&D / Revenue | 4.3% | - | 3.2% | 4.3% | 3.2% | - | 3.5% | 4.5% | 21.7% | - |
| SG&A / Revenue | 20.8% | - | 20.5% | 21.0% | 23.6% | - | 21.7% | 22.9% | 22.7% | - |
| Effective tax rate | 25.1% | - | 23.6% | 21.2% | 21.2% | - | 21.3% | 21.8% | 21.1% | - |
| Return on assets | 5.1% | - | 4.9% | 5.4% | 4.6% | - | 5.4% | 5.4% | 4.7% | - |
| Return on equity | 5.9% | - | 5.7% | 6.1% | 5.2% | - | 6.1% | 6.2% | 5.4% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 7.13 | 7.98 | 6.64 | 8.78 | 8.87 | 8.84 | 9.21 | 9.87 | 9.44 | 4.65 |
| Quick ratio | 6.15 | 6.84 | 5.72 | 7.51 | 7.62 | 7.62 | 7.82 | 8.25 | 7.77 | 3.87 |
| Cash ratio | 4.65 | 5.03 | 4.42 | 6.01 | 5.94 | 6.14 | 6.41 | 6.51 | 5.92 | 3.05 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.16 | 1.15 | 1.17 | 1.13 | 1.13 | 1.13 | 1.13 | 1.13 | 1.16 | 1.29 |
| Liabilities / Assets | 0.14 | 0.13 | 0.14 | 0.11 | 0.11 | 0.12 | 0.11 | 0.11 | 0.14 | 0.23 |
| Efficiency | ||||||||||
| Asset turnover | 0.19 | - | 0.18 | 0.19 | 0.19 | - | 0.19 | 0.20 | 0.20 | - |
| Inventory turnover | 0.43 | - | 0.40 | 0.40 | 0.44 | - | 0.37 | 0.32 | 0.33 | - |
| Days sales outstanding | 223d | - | 239d | 195d | 238d | - | 206d | 243d | 270d | - |
| Days inventory outstanding | 840d | - | 910d | 918d | 825d | - | 993d | 1124d | 1101d | - |
| Days payable outstanding | 154d | - | 181d | 156d | 203d | - | 124d | 104d | 111d | - |
| Cash conversion cycle | 908d | - | 967d | 957d | 861d | - | 1076d | 1263d | 1259d | - |
| Valuation | ||||||||||
| P / E | 213.9x | - | 165.5x | 132.9x | 141.8x | - | 125.7x | 115.6x | 137.5x | - |
| P / B | 12.6x | - | 9.3x | 8.1x | 7.5x | - | 7.7x | 7.0x | 7.4x | - |
| P / S | 56.4x | - | 43.2x | 37.6x | 34.5x | - | 35.1x | 31.3x | 31.9x | - |
| EV / EBITDA | 153.7x | - | 121.1x | 103.2x | 110.7x | - | 99.3x | 88.8x | 103.7x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 12.7% | - | 15.7% | 13.8% | 10.9% | - | 11.0% | 11.1% | 13.7% | - |
| Revenue CAGR (3y) | 12.4% | - | 16.5% | 17.1% | 16.6% | - | 18.9% | 22.3% | 24.0% | - |
| Revenue CAGR (5y) | 19.0% | - | 22.5% | 24.6% | 17.6% | - | 13.0% | 14.2% | 15.8% | - |
| Gross profit growth (YoY) | 13.3% | - | 16.2% | 13.9% | 10.9% | - | 10.5% | 15.0% | 14.2% | - |
| Operating income growth (YoY) | 33.2% | - | 18.0% | 20.6% | 14.4% | - | -2.0% | 13.4% | 18.5% | - |
| Net income growth (YoY) | 24.1% | - | 10.4% | 17.8% | 13.3% | - | -0.3% | 17.3% | 21.4% | - |
| EPS growth (YoY) | 21.6% | - | 7.5% | 18.4% | 15.6% | - | 0.0% | 15.2% | 18.5% | - |
| EPS CAGR (3y) | 18.6% | - | 16.8% | 20.1% | 22.8% | - | 26.0% | 46.8% | 42.8% | - |
| EPS CAGR (5y) | 32.5% | - | 36.7% | - | 21.5% | - | 14.9% | 17.5% | 16.4% | - |
| FCF growth (YoY) | 1226.4% | - | - | - | -83.5% | - | - | - | - | - |
| FCF CAGR (5y) | 57.6% | - | - | - | -10.4% | - | - | - | 44.1% | - |
| Book value growth (YoY) | 9.4% | 9.0% | 17.9% | 18.4% | 18.3% | 21.6% | 11.9% | 15.5% | 18.3% | -3.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Geographic
$83.81M totalUS$70.56M · 84.2%
Non Us$13.26M · 15.8%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing IRADIMED CORP against the 5 most active filers in the same SIC group.
Dividends
$1.24/share trailing 12 months · +93.8% YoY
| Ex-date | Per share |
|---|---|
| May 15, 2026 | $0.2000 |
| Feb 23, 2026 | $0.2000 |
| Dec 17, 2025 | $0.5000 |
| Nov 14, 2025 | $0.1700 |
| Aug 18, 2025 | $0.1700 |
| May 20, 2025 | $0.1700 |
| Feb 24, 2025 | $0.1700 |
| Nov 15, 2024 | $0.1500 |
| Aug 20, 2024 | $0.1500 |
| May 17, 2024 | $0.1500 |
| Dec 21, 2023 | $0.6300 |
| Feb 10, 2023 | $1.0500 |
| Feb 16, 2022 | $1.0000 |